Molecular Docking Analysis of Phytocompounds from Ficus hispida Against Epidermal Growth Factor Receptor Kinase Domain

Year : 2025 | Volume : 03 | Issue : 02 | Page : 48 62
    By

    Lavanya Burra,

  1. Student, Department of Bioinformatics, BioNome Private Limited, Bengaluru, Karnataka, India

Abstract

The Epidermal Growth Factor Receptor (EGFR) kinase domain plays a key role in cancer, as it promotes tumour growth and helps cancer cells survive, making it an important focus for developing treatments. Through comprehensive computational analysis, this study investigates the anticancer potential of phytocompounds from Ficus hispida, a medicinal plant renowned for its diverse bioactive compounds, as novel EGFR inhibitors. Molecular docking techniques using Py Rx software were employed to evaluate the binding interactions of 34 Ficus hispida phytocompounds against the EGFR Kinase domain (PDB ID: 2ITN). Swiss ADME analysis assessed. The top-performing compounds for drug-likeness and pharmacokinetic properties. Protein structure validation was conducted using Ramachandran plot analysis, and molecular interactions were visualized using BIOVIA Discovery Studio. Four phytocompounds demonstrated exceptional binding affinities: Isoderrone (–9.2 Kcal/mol), Ficuisoflavone (–9.1 Kcal/mol), Ficusin A (–8.9 Kcal/mol), and Hispidacine (–8.9 Kcal/mol). All compounds satisfied Lipinski’s rule of five, exhibited favorable ADMET properties, and formed stable hydrogen bonds and hydrophobic interactions with key catalytic residues. The EGFR protein structure showed 85.1% residues in favourable regions, confirming structural reliability. Ficus hispida phytocompounds, particularly Ficusin A and Isoderrone, demonstrate significant potential as natural EGFR inhibitors with favourable pharmacokinetic profiles, warranting further experimental validation for anticancer drug development.

Keywords: Ficus hispida, EGFR kinase domain, molecular docking, molecular dynamics, ADME analysis, drug discovery, phytocompounds, cancer

[This article belongs to International Journal of Cell Biology and Cellular Functions ]

How to cite this article:
Lavanya Burra. Molecular Docking Analysis of Phytocompounds from Ficus hispida Against Epidermal Growth Factor Receptor Kinase Domain. International Journal of Cell Biology and Cellular Functions. 2025; 03(02):48-62.
How to cite this URL:
Lavanya Burra. Molecular Docking Analysis of Phytocompounds from Ficus hispida Against Epidermal Growth Factor Receptor Kinase Domain. International Journal of Cell Biology and Cellular Functions. 2025; 03(02):48-62. Available from: https://journals.stmjournals.com/ijcbcf/article=2025/view=229184


References

  1. Mir PA, Mahajan S, Verma A, Kumar N, Arora M, Nagpal N. In vitro antioxidant and anti-inflammatory potential of Ficus infectoria Pharmacogn Res. 2022;14(2):153–7.
  2. Ahmad W, Jantan I, Bukhari SNA. Tinospora crispa (L.) Hook. f. & Thomson: a survey of its ethnobotanical, phytochemical, and pharmacological perspectives. Front Pharmacol. 2016;7:59.
  3. Patti F, Taheri Y, Sharifi-Rad J, Martorell M, Cho WC, Pezzani R. Erythrina suberosa: Ethnopharmacology, phytochemistry and natural uses. Medicines. 2019;6(4):105. doi:10.3390/medicines6040105.
  4. Sathiyamoorthy J, Sudhakar N. In vitro cytotoxicity and apoptotic assay in HT-29 cell line using Ficus hispida Linn: leaves extract. Pharmacogn Mag. 2018;13(Suppl 4):S756–61. doi:10.4103/pm.pm_319_17.
  5. Peraza-Sánchez SR, Chai HB, Shin YG, Santisuk T, Reutrakul V, Farnsworth NR, et al. Constituents of the leaves and twigs of Ficus hispida. Planta Med. 2002;68(2):186–8. doi:10.1055/s-2002-20257.
  6. Prakash N, Ansari MA, Punitha P, Sharma PK. Indigenous conventional knowledge and utilization of folk bio-medicines among Rongmei tribe of Tamenglong district of Manipur, India. Afr J Tradit Complement Altern Med. 2014;11(3):239–47.
  7. El-Sayed SM, El-Naggar ME, Hussein J, Medhat D, El-Banna M. Effect of Ficus carica leaves extract loaded gold nanoparticles against cisplatin-induced acute kidney injury. Colloids Surf B Biointerfaces. 2019;184:110465.
  8. Ríos JL. Effects of triterpenes on the immune system. J Ethnopharmacol. 2010;128(1):1–14.
  9. Bagla VP, Mokgotho MP, Mampuru LJ. Phytochemicals and cancer – possible molecular targets of phytochemicals in cancer prevention and therapy. In: Rao AV, Rao LG, editors. Phytochemicals – Isolation, Characterisation and Role in Human Health. London: IntechOpen; 2015. Chapter published 2015 Sep 30. doi:10.5772/59873.
  10. Tortora G, Ciardiello F. Drug therapy: epidermal growth factor receptor antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.
  11. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in disease management. Sci Rep. 2023 Aug 17;13(1):13398.
  12. Ritter CA, Arteaga CL. The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol. 2003 Feb;30(1 Suppl 1):3–11.
  13. Gocek E, Moulas AN, Studzinski GP. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Crit Rev Clin Lab Sci. 2014 Jun;51(3):125–37.
  14. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(Suppl 4):2–8.
  15. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009:567486.
  16. Efferth T. Natural products as inhibitors of epidermal growth factor receptor. Forum Immunopathol Dis Ther. 2011;2(4):281–301.
  17. Iqbal J, Abbasi BA, Mahmood T, Kanwal S, Ali B, Shah SA, et al. Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed. 2017 Dec;7(12):1129–50.
  18. Efferth T. Cancer combination therapy of the sesquiterpenoid artesunate and the specific EGFR-tyrosine kinase inhibitor erlotinib. Phytomedicine. 2017;37:58–61.
  19. Das DR, Kumar D, Kumar P, Dash BP, Sprint BP. Molecular docking and its application in search of antisickling agent from Carica papaya. J Appl Biol Biotech. 2020 Jan–Feb;8(1):105–16.
  20. Ghanbari A, Le Gresley A, Naughton D, Kuhnert N, Sirbu D, Ashrafi GH. Biological activities of Ficus carica latex for potential therapeutics in Human Papillomavirus (HPV)-related cervical cancers. Sci Rep. 2019 Jan 31;9(1):1013.
  21. Balogun TA, Ige OM, Alausa AO, Onyeani CO, Tiamiyu ZA, Omoboyowa DA, et al. Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment. Future J Pharm Sci. 2021 Oct 2;7(1):197.
  22. Larbie C, Appiah-Opong R, Acheampong F, Tuffour I, Uto T, Yeboah GA, et al. Anti-proliferative effect of Ficus pumila on human leukemic cell lines. Int J Basic Clin Pharmacol. 2015 Mar–Apr;4(2):330–6.
  23. Tortora G, Ciardiello F. Anti-epidermal growth factor receptor drugs in cancer treatment. Expert Opin Investig Drugs. 2005 Mar;14(3):313–28.
  24. Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist. 2003 Jun;8(6):576–86.
  25. Liao QH, Gao QZ, Wei J, Chou KC. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Med Chem. 2011;7(1):1–9.
  26. Neumann A, Engel V, Mahardhika AB, Schoeder CT, Namasivayam V, Kieć-Kononowicz K, et al. Computational investigations on the binding mode of ligands for the cannabinoid-activated G protein-coupled receptor GPR18. Biomolecules. 2020 May 1;10(5):686.
  27. Arabi AA. Artificial intelligence in drug design: Algorithms, applications, challenges, and ethics. Future Drug Discov. 2021;3(2):FDD59.
  28. Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013 Apr 22;453(1):12–24.
  29. Motta C, Sartini S, Tuccinardi T, Nerini E, Da Settimo F, Martinelli A. Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure–activity relationship analysis, and virtual screening studies. J Med Chem. 2009 Feb 26;52(4):964–75.
  30. Databases used: Osadhi database, PubChem database, BIOVIA Discovery Studio, PyRx, PubSum, Swiss.
Regular Issue Subscription Original Research
Volume 03
Issue 02
Received 21/05/2025
Accepted 05/06/2025
Published 23/08/2025
Publication Time 94 Days
57

Login


My IP

PlumX Metrics